Meta-Analysis
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 24, 2019; 10(6): 234-246
Published online Jun 24, 2019. doi: 10.5306/wjco.v10.i6.234
Metastatic potential and prognostic significance of SOX2: A meta-analysis
Arslaan Javaeed, Sanniya Khan Ghauri
Arslaan Javaeed, Department of Pathology, Poonch Medical College, Azad Kashmir, Rawalakot 1235, Pakistan
Sanniya Khan Ghauri, Department of Emergency Medicine, Shifa International Hospital, Islamabad, 44000, Pakistan
Author contributions: Javaeed A performed the literature search, study design and conception and data extraction, and provided final approval of the manuscript; Ghauri SK performed the data extraction, analysis and interpretation of the data, and drafting of the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Arslaan Javaeed, MBBS, MPhil, MHPE, Assistant Professor, Department of Pathology, Poonch Medical College, Azad Kashmir, Rawalakot 1235, Pakistan. arslaanjavaeed@yahoo.com
Telephone: +92-300-4717057
Received: January 21, 2019
Revised: March 31, 2019
Accepted: April 8, 2019
Published online: June 24, 2019
Processing time: 155 Days and 15.6 Hours
Core Tip

Core tip: SOX2 overexpression is associated with both lymph node and distant metastasis predominantly in cancers of the colon and head and neck. Targeting the biological pathways of SOX2 seems to provide a promising rationale for developing relevant therapeutic interventions.